From seed funding and grants through to growth equity and strategic investment, animal health companies rely on multiple forms of capital over their lifetime. Panellists explore how and when different investors engage, and the criteria they use to assess commercial readiness, including regulatory planning, routes to market, manufacturing decisions, and long-term strategic alignment.
Customer centricity is more than a strategy - it’s a mindset that shapes how the animal health industry engages across the value chain. From manufacturers and distributors to clinics and pet parents, placing the customer at the centre is essential in creating sustainable growth. This panel will bring together senior leaders to discuss how customer expectations are evolving and what it takes to align global business models around those needs to deliver impact across the animal health value chain.
Hugo Denton is the Chief Growth Officer at Devcos and the third generation driving his family’s legacy in the beauty industry. He works with brands around the world to bring new products to life across skin, color, SPF/OTC, personal care, and haircare. Focused on innovation, speed, compliance and quality, Hugo is passionate about helping brands grow while building on Devcos’ 60-year legacy.
An exploration of how illicit compounding intersects with patent protections, market exclusivity, and the proposed EU pharma package revisions shaping the future of pharmaceutical innovation.
With the UPC now established, its impact on national litigation in key life sciences jurisdictions is becoming clearer. This session examines how the UPC’s decisions intersect with proceedings in the UK, France, Germany, the Netherlands, and the US. Speakers will explore recent cases, including BSH v. Electrolux and Fujifilm v. Kodak, assessing the reach of the UPC, divergence in substantive law, and the evolving balance between national and supranational enforcement.
Mike Gilbert is a partner at Marks & Clerk in London. He is an Intellectual Property (IP) lawyer who advises clients in a wide variety of business sectors on issues including litigation and dispute resolution, IP strategy and risk limitation, due diligence projects and commercial and licensing transactions involving IP. His primary focus and expertise, however, lies in life sciences patent litigation where he is considered to be one of the UK’s leading practitioners. He has represented some of the world’s leading biopharmaceutical corporations in complex patent and technical disputes including Genentech, Roche, Chugai, Pfizer, Wyeth, AstraZeneca, MedImmune, Daiichi Sankyo, AbbVie, Amgen and Illumina to name but a few. Mike is well known for his strategic and creative vision and is consistently recommended in various legal directories including the World IP Review, Legal 500, Who's Who Legal and the IAM Patent 1000 guide, which describe him as “always at the top of the pile, especially for pharmaceutical matters”. Mike graduated from Cambridge University in 1989 with a degree in chemical engineering.
This 20 minute session unpacks the implications of G1/23 and explores how recent Board of Appeal decisions are reshaping product launch strategies in Europe. Gain practical insights into how these rulings affect exclusivity, regulatory interplay, and the timing of market entry.
